{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:32:47Z","timestamp":1793079167093,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Consejo Nacional de lnvestigaciones Cient\u00edficas y T\u00e9cnicas","award":["PUE- 22920160100046CO01"],"award-info":[{"award-number":["PUE- 22920160100046CO01"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Consejo Nacional de lnvestigaciones Cient\u00edficas y T\u00e9cnicas","award":["PUE- 22920160100046CO01"],"award-info":[{"award-number":["PUE- 22920160100046CO01"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Consejo Nacional de lnvestigaciones Cient\u00edficas y T\u00e9cnicas","award":["PUE- 22920160100046CO01"],"award-info":[{"award-number":["PUE- 22920160100046CO01"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Consejo Nacional de lnvestigaciones Cient\u00edficas y T\u00e9cnicas","award":["PUE- 22920160100046CO01"],"award-info":[{"award-number":["PUE- 22920160100046CO01"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Consejo Nacional de lnvestigaciones Cient\u00edficas y T\u00e9cnicas","award":["PUE- 22920160100046CO01"],"award-info":[{"award-number":["PUE- 22920160100046CO01"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Consejo Nacional de lnvestigaciones Cient\u00edficas y T\u00e9cnicas","award":["PUE- 22920160100046CO01"],"award-info":[{"award-number":["PUE- 22920160100046CO01"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["PICT 2020\u201300759"],"award-info":[{"award-number":["PICT 2020\u201300759"]}],"id":[{"id":"https:\/\/ror.org\/03stxzb56","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","award":["PICT 2020\u201300759"],"award-info":[{"award-number":["PICT 2020\u201300759"]}],"id":[{"id":"https:\/\/ror.org\/03stxzb56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-62101-5","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:06:47Z","timestamp":1784282807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibitory effects of 2\u2032-nitroflavone and apigenin on EGFR signaling in breast cancer cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Julieta R.","family":"Cebr\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n E.","family":"Berin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana A.","family":"Bojorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariel","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda F.","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana C.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna G.","family":"Miquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"62101_CR1","doi-asserted-by":"publisher","unstructured":"Hong, R. & Xu, B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun. 42, 913\u2013936. https:\/\/doi.org\/10.1002\/cac2.12358 (2022).","DOI":"10.1002\/cac2.12358"},{"key":"62101_CR2","doi-asserted-by":"publisher","unstructured":"Xiong, X. et al. Breast cancer: pathogenesis and treatments. Signal Transduct. Targeted Ther. 10. https:\/\/doi.org\/10.1038\/s41392-024-02108-4 (2025).","DOI":"10.1038\/s41392-024-02108-4"},{"key":"62101_CR3","doi-asserted-by":"publisher","unstructured":"Kinnel, B., Singh, S. K., Oprea-Ilies, G. & Singh, R. Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15041320 (2023)","DOI":"10.3390\/cancers15041320"},{"key":"62101_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won, K. A. & Spruck, C. Triple-negative breast cancer therapy: Current and future perspectives. Int. J. Oncol. 57, 1245\u20131261 (2020).","journal-title":"Int. J. Oncol."},{"key":"62101_CR5","doi-asserted-by":"publisher","unstructured":"Agostinetto, E., Curigliano, G. & Piccart, M. Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar. Cell Rep. Med. 5. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101575 (2024).","DOI":"10.1016\/j.xcrm.2024.101575"},{"key":"62101_CR6","doi-asserted-by":"crossref","unstructured":"Emara, H. M., Allam, N. K. & Youness, R. A. A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline. Discov. Oncol. 16, 547 (2025).","DOI":"10.1007\/s12672-025-02227-6"},{"key":"62101_CR7","doi-asserted-by":"publisher","first-page":"188789","DOI":"10.1016\/j.bbcan.2022.188789","volume":"1877","author":"X Li","year":"2022","unstructured":"Li, X., Zhao, L., Chen, C., Nie, J. & Jiao, B. Can EGFR be a therapeutic target in breast cancer? Biochim. et Biophys. Acta (BBA) Rev. Cancer 1877, 188789 (2022).","journal-title":"Biochim. et Biophys. Acta (BBA) Rev. Cancer"},{"key":"62101_CR8","doi-asserted-by":"publisher","first-page":"Preprintathttps","DOI":"10.1016\/j.rechem.2024.101490","volume":"7","author":"R Mariam Raju","year":"2024","unstructured":"Mariam Raju, R., Joy A, J., Nulgumnalli Manjunathaiah, R., Justin, A. & Prashantha Kumar, B. R. EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review. Results Chem. 7, Preprintathttpsdoiorg101016jrechem2024101490 (2024).","journal-title":"Results Chem."},{"key":"62101_CR9","doi-asserted-by":"publisher","unstructured":"Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M. & Gouda, A. M. Globally approved egfr inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules 26. https:\/\/doi.org\/10.3390\/molecules26216677 (2021).","DOI":"10.3390\/molecules26216677"},{"key":"62101_CR10","doi-asserted-by":"publisher","unstructured":"Duggirala, K. B., Lee, Y. & Lee, K. Chronicles of EGFR tyrosine kinase inhibitors: Targeting EGFR C797S containing triple mutations. Biomol. Ther. 30, 19\u201327. https:\/\/doi.org\/10.4062\/biomolther.2021.047 (2022).","DOI":"10.4062\/biomolther.2021.047"},{"key":"62101_CR11","doi-asserted-by":"crossref","unstructured":"Maennling, A. E. et al. Molecular targeting therapy against egfr family in breast cancer: Progress and future potentials. Cancers (Basel) 11, 1826 (2019).","DOI":"10.3390\/cancers11121826"},{"key":"62101_CR12","doi-asserted-by":"publisher","unstructured":"Uribe, M. L., Marrocco, I. & Yarden, Y. Cancers EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. https:\/\/doi.org\/10.3390\/cancers (2021).","DOI":"10.3390\/cancers"},{"key":"62101_CR13","doi-asserted-by":"crossref","unstructured":"Iancu, G. et al. Tyrosine kinase inhibitors in breast cancer (Review). Exp. Ther. Med. 23, 114 (2021).","DOI":"10.3892\/etm.2021.11037"},{"key":"62101_CR14","doi-asserted-by":"publisher","unstructured":"Liu, Q. et al. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol. Cancer 17. https:\/\/doi.org\/10.1186\/s12943-018-0793-1 (2018).","DOI":"10.1186\/s12943-018-0793-1"},{"key":"62101_CR15","doi-asserted-by":"publisher","unstructured":"Bansal, I., Pandey, A. K. & Ruwali, M. Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges. Front. Pharmacol. 14. https:\/\/doi.org\/10.3389\/fphar.2023.1244597 (2023).","DOI":"10.3389\/fphar.2023.1244597"},{"key":"62101_CR16","doi-asserted-by":"publisher","unstructured":"Singh, S., Sadhukhan, S. & Sonawane, A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochim. Biophys. Acta Rev. Cancer 1878 (2023). https:\/\/doi.org\/10.1016\/j.bbcan.2023.188967","DOI":"10.1016\/j.bbcan.2023.188967"},{"key":"62101_CR17","doi-asserted-by":"publisher","unstructured":"Ali, R. & Wendt, M. K. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct. Targeted Ther. 2. https:\/\/doi.org\/10.1038\/sigtrans.2016.42 (2017).","DOI":"10.1038\/sigtrans.2016.42"},{"key":"62101_CR18","doi-asserted-by":"publisher","unstructured":"Chemmalar, S. et al. Busting the Breast Cancer with AstraZeneca\u2019s Gefitinib. Adv. Pharmacol. Pharm. Sci. 2023. https:\/\/doi.org\/10.1155\/2023\/8127695 (2023).","DOI":"10.1155\/2023\/8127695"},{"key":"62101_CR19","doi-asserted-by":"publisher","unstructured":"Sudhesh Dev, S., Farghadani, R., Zainal Abidin, S. A., Othman, I. & Naidu, R. Flavonoids as receptor tyrosine kinase inhibitors in lung cancer. J. Funct. Foods 110. https:\/\/doi.org\/10.1016\/j.jff.2023.105845 (2023).","DOI":"10.1016\/j.jff.2023.105845"},{"key":"62101_CR20","doi-asserted-by":"publisher","unstructured":"Vachetta, V. S., Marder, M., Troncoso, M. F. & Elola, M. T. Opportunities, obstacles and current challenges of flavonoids for luminal and triple-negative breast cancer therapy. Eur. J. Med. Chem. Rep. 6. https:\/\/doi.org\/10.1016\/j.ejmcr.2022.100077 (2022).","DOI":"10.1016\/j.ejmcr.2022.100077"},{"key":"62101_CR21","doi-asserted-by":"publisher","unstructured":"Mir, S. A. et al. Flavonoids as promising molecules in the cancer therapy: An insight. Curr. Res. Pharmacol. Drug Discov. 6 (2024). https:\/\/doi.org\/10.1016\/j.crphar.2023.100167","DOI":"10.1016\/j.crphar.2023.100167"},{"key":"62101_CR22","unstructured":"Kikuchi, H., Yuan, B., Hu, X. & Okazaki, M. Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents. Am. J. Cancer Res. 9 (2019)."},{"key":"62101_CR23","doi-asserted-by":"publisher","unstructured":"Liskova, A. et al. Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles. EPMA J. 12, 155\u2013176. https:\/\/doi.org\/10.1007\/s13167-021-00242-5 (2021).","DOI":"10.1007\/s13167-021-00242-5"},{"key":"62101_CR24","doi-asserted-by":"crossref","unstructured":"Lee, H. H., Jung, J., Moon, A., Kang, H. & Cho, H. Antitumor and anti-invasive effect of apigenin on human breast carcinoma through suppression of IL-6 expression. Int J. Mol. Sci 20, 3143 (2019).","DOI":"10.3390\/ijms20133143"},{"key":"62101_CR25","doi-asserted-by":"crossref","unstructured":"Chen, Z. S. et al. Apigenin combined with gefitinib blocks autophagy flux and induces apoptotic cell death through inhibition of HIF-1\u03b1, c-Myc, p-EGFR, and glucose metabolism in EGFR L858R+T790M-Mutated H1975 cells. Front. Pharmacol. 10, 260 (2019).","DOI":"10.3389\/fphar.2019.00260"},{"key":"62101_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14715\/cmb\/2018.64.8.1","volume":"64","author":"A Kaba\u0142a-Dzik","year":"2018","unstructured":"Kaba\u0142a-Dzik, A. et al. Flavonoids, bioactive components of propolis, exhibit cytotoxic activity and induce cell cycle arrest and apoptosis in human breast cancer cells MDA-MB-231 and MCF-7-A comparative study. Cell. Mol. Biol. 64, 1\u201310 (2018).","journal-title":"Cell. Mol. Biol."},{"key":"62101_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00210-018-1486-4","volume":"391","author":"I Vrhovac Maduni\u0107","year":"2018","unstructured":"Vrhovac Maduni\u0107, I. et al. Apigenin, a dietary flavonoid, induces apoptosis, DNA damage, and oxidative stress in human breast cancer MCF-7 and MDA MB-231 cells. Naunyn Schmiedebergs Arch. Pharmacol. 391, 537\u2013550 (2018).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"62101_CR28","doi-asserted-by":"publisher","unstructured":"Naponelli, V., Rocchetti, M. T. & Mangieri, D. Apigenin molecular mechanisms and therapeutic potential against cancer spreading. Int. J. Mol. Sci. 25. https:\/\/doi.org\/10.3390\/ijms25105569 (2024).","DOI":"10.3390\/ijms25105569"},{"key":"62101_CR29","doi-asserted-by":"publisher","unstructured":"Rahmani, A. H. et al. The potential role of apigenin in cancer prevention and treatment. Molecules 27 (2022). https:\/\/doi.org\/10.3390\/molecules27186051","DOI":"10.3390\/molecules27186051"},{"key":"62101_CR30","doi-asserted-by":"publisher","unstructured":"Fossatelli, L., Maroccia, Z., Fiorentini, C. & Bonucci, M. Resources for human health from the plant kingdom: The potential role of the flavonoid apigenin in cancer counteraction. Int. J. Mol. Sci. 25. https:\/\/doi.org\/10.3390\/ijms25010251 (2024).","DOI":"10.3390\/ijms25010251"},{"key":"62101_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.biopha.2018.03.111","volume":"102","author":"WJ Hu","year":"2018","unstructured":"Hu, W. J., Liu, J., Zhong, L. K. & Wang, J. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling. Biomed. Pharmacother. 102, 681\u2013688 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"62101_CR32","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1016\/j.bmc.2005.12.021","volume":"14","author":"M C\u00e1rdenas","year":"2006","unstructured":"C\u00e1rdenas, M., Marder, M., Blank, V. C. & Roguin, L. P. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg. Med. Chem. 14, 2966\u20132971 (2006).","journal-title":"Bioorg. Med. Chem."},{"key":"62101_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.canlet.2008.03.062","volume":"268","author":"MG C\u00e1rdenas","year":"2008","unstructured":"C\u00e1rdenas, M. G., Blank, V. C., Marder, M. & Roguin, L. P. 2\u2032-Nitroflavone induces cell cycle arrest and apoptosis in HeLa human cervical carcinoma cells. Cancer Lett. 268, 146\u2013157 (2008).","journal-title":"Cancer Lett."},{"key":"62101_CR34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ijc.24361","volume":"125","author":"MG C\u00e1rdenas","year":"2009","unstructured":"C\u00e1rdenas, M. G., Zotta, E., Marder, M. & Roguin, L. P. In vitro induction of apoptosis and in vivo effects of a flavone nitroderivative in murine mammary adenocarcinoma cells. Int. J. Cancer. 125, 222\u2013228 (2009).","journal-title":"Int. J. Cancer"},{"key":"62101_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-024-02497-7","author":"JM Anselmi Relats","year":"2024","unstructured":"Anselmi Relats, J. M. et al. Synergistic effect of the sphingosine kinase inhibitor safingol in combination with 2\u2032-nitroflavone in breast cancer. J. Mol. Med. https:\/\/doi.org\/10.1007\/s00109-024-02497-7 (2024).","journal-title":"J. Mol. Med."},{"key":"62101_CR36","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/CAD.0b013e328353f947","volume":"23","author":"MG C\u00e1rdenas","year":"2012","unstructured":"C\u00e1rdenas, M. G., Blank, V. C., Marder, M. N. & Roguin, L. P. 2\u2032-Nitroflavone induces apoptosis and modulates mitogen-activated protein kinase pathways in human leukaemia cells. Anticancer Drugs. 23, 815\u2013826 (2012).","journal-title":"Anticancer Drugs"},{"key":"62101_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-34214-w","author":"VS Vachetta","year":"2026","unstructured":"Vachetta, V. S. et al. 2\u2032-Nitroflavone targets PARP1 and alters cytoskeleton to inhibit triple-negative breast cancer progression. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-025-34214-w (2026).","journal-title":"Sci. Rep."},{"key":"62101_CR38","doi-asserted-by":"crossref","unstructured":"Landegren, U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J. lmmunol. Methods 67, 379\u2013388 (1984).","DOI":"10.1016\/0022-1759(84)90477-0"},{"key":"62101_CR39","doi-asserted-by":"publisher","unstructured":"Ozyurt, R. & Ozpolat, B. Molecular mechanisms of anti-estrogen therapy resistance and novel targeted therapies. Cancers 14 (2022). https:\/\/doi.org\/10.3390\/cancers14215206","DOI":"10.3390\/cancers14215206"},{"key":"62101_CR40","doi-asserted-by":"publisher","unstructured":"Sigismund, S., Avanzato, D. & Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol. 12, 3\u201320. https:\/\/doi.org\/10.1002\/1878-0261.12155 (2018).","DOI":"10.1002\/1878-0261.12155"},{"key":"62101_CR41","doi-asserted-by":"crossref","unstructured":"Chen, Q. et al. Truncated PARP1 mediates ADP-ribosylation of RNA polymerase III for apoptosis. Cell Discov. 8, 3 (2022).","DOI":"10.1038\/s41421-021-00355-1"},{"key":"62101_CR42","doi-asserted-by":"publisher","unstructured":"Marvalim, C., Datta, A. & Lee, S. C. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics 13, 1421\u20131442. https:\/\/doi.org\/10.7150\/thno.81847 (2023).","DOI":"10.7150\/thno.81847"},{"key":"62101_CR43","unstructured":"Chou, T. C. & Martin, N. CompuSyn For Drug Combinations User\u2019s Guide A Computer Program for Quantitation of Synergism and Antagonism in Drug CompuSyn for drug combinations compusyn software license agreement (2004)."},{"key":"62101_CR44","doi-asserted-by":"publisher","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10 (2006).","DOI":"10.1124\/pr.58.3.10"},{"key":"62101_CR45","first-page":"925","volume":"1","author":"TC Chou","year":"2011","unstructured":"Chou, T. C. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am. J. Cancer Res. 1, 925\u2013954 (2011).","journal-title":"Am. J. Cancer Res."},{"key":"62101_CR46","doi-asserted-by":"publisher","unstructured":"Foucquier, J. & Guedj, M. Analysis of drug combinations: current methodological landscape. Pharmacol. Res. Perspect. 3. https:\/\/doi.org\/10.1002\/prp2.149 (2015).","DOI":"10.1002\/prp2.149"},{"key":"62101_CR47","doi-asserted-by":"publisher","unstructured":"Duarte, D. & Vale, N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res. Pharmacol. Drug Discov. 3. https:\/\/doi.org\/10.1016\/j.crphar.2022.100110 (2022).","DOI":"10.1016\/j.crphar.2022.100110"},{"key":"62101_CR48","doi-asserted-by":"publisher","unstructured":"Ciardiello, F. et al. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat. Rev. 122. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102664 (2024).","DOI":"10.1016\/j.ctrv.2023.102664"},{"key":"62101_CR49","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1152\/physrev.00030.2015","volume":"96","author":"J Chen","year":"2016","unstructured":"Chen, J. et al. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol. Rev. 96, 1025\u20131069 (2016).","journal-title":"Physiol. Rev."},{"key":"62101_CR50","doi-asserted-by":"publisher","unstructured":"Ayati, A. et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorgan. Chem. 99. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103811 (2020).","DOI":"10.1016\/j.bioorg.2020.103811"},{"key":"62101_CR51","doi-asserted-by":"publisher","unstructured":"Rahmani, A. H. et al. The potential role of apigenin in cancer prevention and treatment. Molecules 27. https:\/\/doi.org\/10.3390\/molecules27186051 (2022).","DOI":"10.3390\/molecules27186051"},{"key":"62101_CR52","doi-asserted-by":"publisher","unstructured":"Daly, G. R. et al. PARP inhibitors in breast cancer: a short communication. Curr. Oncol. Rep. 26, 103\u2013113. https:\/\/doi.org\/10.1007\/s11912-023-01488-0 (2024).","DOI":"10.1007\/s11912-023-01488-0"},{"key":"62101_CR53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10549-014-3230-1","volume":"149","author":"AR Green","year":"2015","unstructured":"Green, A. R. et al. Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res. Treat. 149, 353\u2013362 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"62101_CR54","first-page":"133","volume":"80","author":"AH Hasani","year":"2018","unstructured":"Hasani, A. H. P53 and cyclin B1 mediate apoptotic effects of apigenin and rutin in ER\u03b1+-breast cancer MCF-7 cells. J. Teknol. 80, 133\u2013140 (2018).","journal-title":"J. Teknol"},{"key":"62101_CR55","doi-asserted-by":"crossref","unstructured":"Lin, C. H. et al. Flavones inhibit breast cancer proliferation through the Akt\/FOXO3a signaling pathway. BMC Cancer 15, 958 (2015).","DOI":"10.1186\/s12885-015-1965-7"},{"key":"62101_CR56","first-page":"212","volume":"25","author":"X Cao","year":"2013","unstructured":"Cao, X. et al. Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells. Chin. J. Cancer Res. 25, 212\u2013222 (2013).","journal-title":"Chin. J. Cancer Res."},{"key":"62101_CR57","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12094-020-02461-0","volume":"23","author":"AK Shendge","year":"2021","unstructured":"Shendge, A. K., Chaudhuri, D., Basu, T. & Mandal, N. A natural flavonoid, apigenin isolated from Clerodendrum viscosum leaves, induces G2\/M phase cell cycle arrest and apoptosis in MCF-7 cells through the regulation of p53 and caspase-cascade pathway. Clin. Transl. Oncol. 23, 718\u2013730 (2021).","journal-title":"Clin. Transl. Oncol."},{"key":"62101_CR58","doi-asserted-by":"crossref","unstructured":"Ou, M. et al. Mechanism of Apigenin against breast cancer stem cells: network pharmacology and experimental validation. Front. Pharmacol. 15, 1496664 (2024).","DOI":"10.3389\/fphar.2024.1496664"},{"key":"62101_CR59","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0960-894X(97)00343-0","volume":"7","author":"M Marder","year":"1997","unstructured":"Marder, M. et al. Synthesis of halogenated\/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor. Bioorg. Med. Chem. Lett. 7, 2003\u20132008 (1997).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"62101_CR60","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1021\/pr1011476","volume":"10","author":"C Welinder","year":"2011","unstructured":"Welinder, C. & Ekblad, L. Coomassie staining as loading control in Western blot analysis. J. Proteome Res. 10, 1416\u20131419 (2011).","journal-title":"J. Proteome Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62101-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62101-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62101-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:45:38Z","timestamp":1793076338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62101-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62101-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32769"}}